|
1
|
Barbui T, Thiele J, Gisslinger H,
Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A and Tefferi A:
The 2016 WHO classification and diagnostic criteria for
myeloproliferative neoplasms: Document summary and in-depth
discussion. Blood Cancer J. 8(15)2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Arber DA, Orazi A, Hasserjian R, Thiele J,
Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW:
The 2016 revision to the World Health Organization classification
of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405.
2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Lussana F and Rambaldi A: Inflammation and
myeloproliferative neoplasms. J Autoimmun. 85:58–63.
2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Challen GA and Goodell MA: Clonal
hematopoiesis: Mechanisms driving dominance of stem cell clones.
Blood. 136:1590–1598. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Bousoik E and Montazeri Aliabadi H: ‘Do we
know jack’ about JAK? A closer look at JAK/STAT signaling pathway.
Front Oncol. 8(287)2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Palumbo GA, Stella S, Pennisi MS, Pirosa
C, Fermo E, Fabris S, Cattaneo D and Iurlo A: The role of new
technologies in myeloproliferative neoplasms. Front Oncol.
9(321)2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Campbell PJ and Green AR: The
myeloproliferative disorders. N Engl J Med. 355:2452–2466.
2006.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Tefferi A: Myeloproliferative neoplasms: A
decade of discoveries and treatment advances. Am J Hematol.
91:50–58. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Baxter EJ, Scott LM, Campbell PJ, East C,
Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N,
et al: Acquired mutation of the tyrosine kinase JAK2 in human
myeloproliferative disorders. Lancet. 365:1054–1061.
2005.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Chen E and Mullally A: How does JAK2V617F
contribute to the pathogenesis of myeloproliferative neoplasms?
Hematology Am Soc Hematol Educ Program. 2014:268–276.
2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Hubbard SR: Mechanistic insights into
regulation of JAK2 tyrosine kinase. Front Endocrinol (Lausanne).
8(361)2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Geay A, Aral B, Bourgeois V, Martin P,
Airaud F, Garrec C, Bézieau S, Gardie B and Girodon F: Diagnosis of
exon 12-positive polycythemia vera rescued by NGS. Clin Case Rep.
8:790–792. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Bader MS and Meyer SC: JAK2 in
myeloproliferative neoplasms: Still a protagonist. Pharmaceuticals
(Basel) 15:. 160:1–13. 2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Scott LM, Tong W, Levine RL, Scott MA,
Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison
CN, et al: JAK2 exon 12 mutations in polycythemia vera and
idiopathic erythrocytosis. N Engl J Med. 356:459–468.
2007.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kanduła Z, Janowski M, Więckowska B,
Paczkowska E and Lewandowski K: JAK2V617F variant allele frequency,
non-driver mutations, single-nucleotide variants and polycythemia
vera outcome. J Cancer Res Clin Oncol. 149:4789–4803.
2023.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Hu L, Pu L, Ding Y, Li M, Cabanero M, Xie
J, Zhou D, Yang D, Zhang C, Wang H, et al: Relationship between
JAK2V617F mutation, allele burden and coagulation function in
Ph-negative myeloproliferative neoplasms. Hematology. 22:354–360.
2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Arellano-Rodrigo E, Alvarez-Larrán A,
Reverter JC, Colomer D, Villamor N, Bellosillo B and Cervantes F:
Platelet turnover, coagulation factors, and soluble markers of
platelet and endothelial activation in essential thrombocythemia:
Relationship with thrombosis occurrence and JAK 2 V617F allele
burden. Am J Hematol. 84:102–108. 2009.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Villanueva A, Poon KS, Gallardo CA, Chai
CN, Chiu L, Yan B, Ding CSL, Yong KJ, Zhou J, Lee J, et al: A novel
JAK2 R564* variant in a patient with thrombocytosis. Int
J Lab Hematol. 42:e38–e41. 2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Alghasham N, Alnouri Y, Abalkhail H and
Khalil S: Detection of mutations in JAK2 exons 12-15 by Sanger
sequencing. Int J Lab Hematol. 38:34–41. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Skov V: Next generation sequencing in
MPNs. Lessons from the past and prospects for use as predictors of
prognosis and treatment responses. Cancers (Basel).
12(2194)2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Loscocco GG, Guglielmelli P and Vannucchi
AM: Impact of mutational profile on the management of
myeloproliferative neoplasms: A short review of the emerging data.
Onco Targets Ther. 13:12367–12382. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Sokol J, Skerenova M, Ivankova J, Simurda
T and Stasko J: Association of genetic variability in selected
genes in patients with deep vein thrombosis and platelet
hyperaggregability. Clin Appl Thromb Hemost. 24:1027–1032.
2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zhong Y, Wu J, Ma R, Cao H, Wang Z, Ding
J, Cheng L, Feng J and Chen B: Association of Janus kinase 2 (JAK2)
polymorphisms with acute leukemia susceptibility. Int J Lab
Hematol. 34:248–253. 2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Yang L, Liu D, Liang S, Guo R, Zhang Z, Xu
H, Yang C and Zhu Y: Janus kinase 2 polymorphisms are associated
with risk in patients with gastric cancer in a Chinese population.
PLoS One. 8(e64628)2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Maslah N, Verger E, Schlageter MH, Miclea
JM, Kiladjian JJ, Giraudier S, Chomienne C and Cassinat B:
Next-generation sequencing for JAK2 mutation testing: Advantages
and pitfalls. Ann Hematol. 98:111–118. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
De Carvalho TG, De Carvalho AC, Maia DC,
Ogawa JK, Carvalho AL and Vettore AL: Search for mutations in
signaling pathways in head and neck squamous cell carcinoma. Oncol
Rep. 30:334–340. 2013.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Silva GA, Ramasawmy R, Boechat AL, Morais
AC, Carvalho BK, Sousa KB, Souza VC, Cunha MG, Barletta-Naveca RH,
Santos MP and Naveca FG: Association of TNF-1031 C/C as a potential
protection marker for leprosy development in Amazonas state
patients, Brazil. Hum. Immunol. 76:137–141. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Lis JT: Fractionation of DNA fragments by
polyethylene glycol induced precipitation. Methods Enzymol.
65:347–353. 1980.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Paithankar KR and Prasad KS: Precipitation
of DNA by polyethylene glycol and ethanol. Nucleic Acids Res.
19(1346)1991.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Macedo LC, Santos BC, Pagliarini-e-Silva
S, Pagnano KB, Rodrigues C, Quintero FC, Ferreira ME, Baraldi EC,
Ambrosio-Albuquerque EP, Sell AM and Visentainer JE: JAK2 46/1
haplotype is associated with JAK2 V617F-positive myeloproliferative
neoplasms in Brazilian patients. Int J Lab Hematol. 37:654–660.
2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Macedo LC, de Cesare Quintero F,
Pagliari-E-Silva S, Pagnano KB, Rodrigues C, de Alencar JB, Sell AM
and Visentainer JE: Association of TNF polymorphisms with JAK2
(V617F) myeloproliferative neoplasms in Brazilian patients. Blood
Cells Mol Dis. 57:54–57. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
da Silva RR, Domingues Hatzlhofer BL,
Machado CG, Lima AS, de Albuquerque DM, dos Santos MN, Fertrin KY,
Costa FF, Araújo Ada S and Bezerra MA: JAK2 V617F mutation
prevalence in myeloproliferative neoplasms in Pernambuco, Brazil.
Genet Test Mol Biomarkers. 16:802–805. 2012.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Hasselbalch HC: Time for revival of the
red blood cell count and red cell mass in the differential
diagnosis between essential thrombocythemia and polycythemia vera?
Haematologica. 104:2119–2125. 2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Langabeer SE: The role of a low
erythropoietin level in the diagnosis of JAK2 exon 12-mutated
polycythemia vera. Blood Cells Mol Dis. 80(102377)2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Maslah N, Soret J, Dosquet C, Vercellino
L, Belkhodja C, Schlageter MH, Cassinat B, Kiladjian JJ, Chomienne
C and Giraudier S: Masked polycythemia vera: analysis of a single
center cohort of 2480 red cell masses. Haematologica. 105:e95–e97.
2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Stefaniuk P, Szymczyk A and Podhorecka M:
The neutrophil to lymphocyte and lymphocyte to monocyte ratios as
new prognostic factors in hematological malignancies-a narrative
review. Cancer Manag Res. 12:2961–2977. 2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Mulas O, Mola B, Madeddu C, Caocci G,
Macciò A and Nasa GL: Prognostic role of cell blood count in
chronic myeloid neoplasm and acute myeloid leukemia and its
possible implications in hematopoietic stem cell transplantation.
Diagnostics (Basel). 12(2493)2022.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Vannucchi AM, Masala G, Antonioli E,
Chiara Susini M, Guglielmelli P, Pieri L, Maggi L, Caini S, Palli
D, Bogani C, et al: Increased risk of lymphoid neoplasms in
patients with Philadelphia chromosome-negative myeloproliferative
neoplasms. Cancer Epidemiol. Biomarkers Prev. 18:2068–2073.
2009.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Garcia-Gisbert N, Camacho L,
Fernández-Ibarrondo L, Fernández-Rodriguez C, Longarón R, Gibert J,
Angona A, Andrade-Campos M, Salar A, Besses C and Bellosillo B:
Analysis of saliva samples and cluster of differentiation 3 (CD3)+
lymphocytes as a source of germline DNA in myeloproliferative
neoplasms. Br J Haematol. 189:e204–e207. 2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Sunu C, Gunes AK, Akat GK, Kalpakci Y,
Ceran F, Dagdas S and Ozet G: The evaluation of patients with
essential thrombocythemia in terms of risk of thrombosis. Rev Assoc
Med Bras (1992). 67:385–389. 2021.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Yahouédéhou SCMA, da Guarda CC, Figueiredo
CVB, Santiago RP, Carvalho SP, Fiuza LM, Ndidi US, Oliveira RM,
Carvalho MOS, Nascimento VML, et al: Hydroxyurea alters
hematological, biochemical and inflammatory biomarkers in Brazilian
children with SCA: Investigating associations with βS haplotype and
α-thalassemia. PLoS One. 14(e0218040)2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Davidson TM: The good, the bad, and the
ugly. Arch Otolaryngol Head Neck Surg. 123(115)1997.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Buxhofer-Ausch V, Steurer M, Sormann S,
Schloegl E, Schimetta W, Gisslinger B, Ruckser R, Gastl G and
Gisslinger H: Influence of platelet and white blood cell counts on
major thrombosis-analysis from a patient registry in essential
thrombocythemia. Eur J Haematol. 97:511–516. 2016.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Kaifie A, Kirschner M, Wolf D, Maintz C,
Hänel M, Gattermann N, Gökkurt E, Platzbecker U, Hollburg W,
Göthert JR, et al: Bleeding, thrombosis, and anticoagulation in
myeloproliferative neoplasms (MPN): Analysis from the German
SAL-MPN-registry. J Hematol Oncol. 9(18)2016.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Matsuura S, Thompson CR, Belghasem ME,
Bekendam RH, Piasecki A, Leiva O, Ray A, Italiano J, Yang M,
Merill-Skoloff G, et al: Platelet dysfunction and thrombosis in
JAK2V617F-mutated primary myelofibrotic mice.
Arterioscler Thromb Vasc Biol. 40:e262–e272. 2020.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Accurso V, Santoro M, Mancuso S,
Napolitano M, Carlisi M, Mattana M, Russo C, Di Stefano A, Sirocchi
D and Siragusa S: The essential thrombocythemia in 2020: What we
know and where we still have to dig deep. Clin Med Insights Blood
Disord. 13(2634853520978210)2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Chang YC, Lin HC, Chiang YH, Chen CG,
Huang L, Wang WT, Cheng CC, Lin J, Chang YF, Chang MC, et al:
Targeted next-generation sequencing identified novel mutations in
triple-negative myeloproliferative neoplasms. Med Oncol.
34(83)2017.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Milosevic Feenstra JD, Nivarthi H,
Gisslinger H, Leroy E, Rumi E, Chachoua I, Bagienski K, Kubesova B,
Pietra D, Gisslinger B, et al: Whole-exome sequencing identifies
novel MPL and JAK2 mutations in triple-negative myeloproliferative
neoplasms. Blood. 127:325–332. 2016.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Schulze S, Stengel R, Jaekel N, Wang SY,
Franke GN, Roskos M, Schneider M, Niederwieser D and Al-Ali HK:
Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F-
and MPLW515 L-positive myelofibrosis. Genes Chromosom Cancer.
58:747–755. 2019.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Marty C, Saint-Martin C, Pecquet C,
Grosjean S, Saliba J, Mouton C, Leroy E, Harutyunyan AS, Abgrall
JF, Favier R, et al: Germ-line JAK2 mutations in the kinase domain
are responsible for hereditary thrombocytosis and are resistant to
JAK2 and HSP90 inhibitors. Blood. 123:1372–1383. 2014.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Etheridge SL, Cosgrove ME, Sangkhae V,
Corbo LM, Roh ME, Seeliger MA, Chan EL and Hitchcock IS: A novel
activating, germline JAK2 mutation, JAK2R564Q, causes familial
essential thrombocytosis. Blood. 123:1059–1068. 2014.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Gou P, Zhang W and Giraudier S: Insights
into the potential mechanisms of JAK2V617F somatic mutation
contributing distinct phenotypes in myeloproliferative neoplasms.
Int J Mol Sci. 23(1013)2022.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Zhao L, Ma Y, Seemann J and Huang LJ: A
regulating role of the JAK2 FERM domain in hyperactivation of
JAK2(V617F). Biochem J. 426:91–98. 2010.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Kapralova K, Horvathova M, Pecquet C,
Fialova Kucerova J, Pospisilova D, Leroy E, Kralova B, Milosevic
Feenstra JD, Schischlik F, Kralovics R, et al: Cooperation of germ
line JAK2 mutations E846D and R1063H in hereditary erythrocytosis
with megakaryocytic atypia. Blood. 128:1418–1423. 2016.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Lanikova L, Babosova O, Swierczek S, Wang
L, Wheeler DA, Divoky V, Korinek V and Prchal JT: Coexistence of
gain-of-function JAK2 germ line mutations with
JAK2V617F in polycythemia vera. Blood.
128:2266–2270. 2016.PubMed/NCBI View Article : Google Scholar
|
